# OnCo record capmatinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/capmatinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "capmatinib" ;
  schema:name "Capmatinib"@en ;
  schema:alternateName "INC280"@en, "Tabrecta" ;
  schema:description "Capmatinib is a targeted pill for the small group of lung cancers driven by a MET exon 14 skipping mutation, found by tumour sequencing."@en ;
  schema:url <https://onco.cc/drugs/capmatinib/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Capmatinib> ;
  schema:citation <https://doi.org/10.1056/NEJMoa2002787>, <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=capmatinib> ;
  onco:status "approved" ;
  onco:tag "gap-fill" ;
  onco:modality "Small-molecule MET tyrosine kinase inhibitor" ;
  onco:approval "US 2020: Metastatic NSCLC with a MET exon 14 skipping mutation (accelerated approval)" ;
  onco:acceleratedApproval "US 2020-05-06: Adult patients with mNSCLC whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test" ;
  onco:acceleratedApprovalConfirmed "US 2022-08-10: Adult patients with mNSCLC whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test" ;
  onco:related <https://onco.cc/biomarkers/met-ex14/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/met-altered-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/met/> ;
  onco:drugs <https://onco.cc/drugs/tepotinib/>, <https://onco.cc/drugs/crizotinib/> ;
  onco:companies <https://onco.cc/companies/novartis/> ;
  onco:trials <https://onco.cc/trials/geometry-mono-1/>, <https://onco.cc/trials/nct03040973/>, <https://onco.cc/trials/nct05488314/> .